Yakup Ergün· @dr_yakupergun · X·· 23 小时前评分70
正文 · 机器翻译
#ESMO26 | VOLGA
新辅助 EV + 围手术期 durvalumab 在 MIBC 中展现出令人印象深刻的结果✅
一个重要细节：约 25% 的患者并非不符合顺铂治疗条件，而是拒绝接受顺铂治疗。
因此，该方案的潜在适用范围可能超越不符合顺铂治疗条件的患者
261 浏览 · 2 赞 · 1 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org#ESMO26 | VOLGA | Presidential Symposium-1 In cisplatin-ineligible/refusing MIBC, neoadjuvant EV + perioperative durvalumab significantly improved EFS and OS vs the control arm. EFS: HR 0.55 (24-month: 78% vs 69%) OS: HR 0.58 (24-month: 83% vs 75%) pCR: 45% vs 10% Impressive results! Unlike KEYNOTE-905/EV-303, EV was administered only in the neoadjuvant setting, with no adjuvant EV. I’m looking forward to the discussion during the session.在 X 查看被引用的帖子
来源：Yakup Ergün · x.com